Fig. 4.
Pooled proportion of survivors in recent virotherapies trials for rGBM at (A) 24 months and (B) 36 months. Studies on virotherapy clinical trials reporting 24-month and 36-month overall survival for rGBM are included. Survivors represent the number of patients surviving at 24 or 36 months. Total represents the total number of rGBM patients in a trial. Given the heterogeneity of designs, pooling of proportion of patients was performed via a random effects model.